BUSCADOR
HOME > PROYECTOS DE INVESTIGACIÓN > TumorOut (Innovative mRNA vaccine against lung cancer)

TumorOut (Innovative mRNA vaccine against lung cancer)

Innovative platform of targeted polymeric nanoparticles for efficient personalized therapy against lung cancer

Fuente de financiación:
Gobierno de España
Entidad financiadora:
Tipología del proyecto:
Proyecto consorcio europeo
Periodo:
01/01/2023 a 31/12/2025
Financiación:
250.000€
Estado del proyecto:
ACTIVO

This project involves the coordinated activities of 6 european research centres coordinated by IQS to develop a novel therapy to treat lung cancer. Non-small cell lung cancer (NSCLC) treatment shows unprecedented improvement with immune checkpoint inhibitors (ICIs) but only a minority of NSCLC patients (25%) demonstrate long-term benefit. Our preliminary data and working hypothesis is that therapeutic mRNA vaccination, coupled with co-targeting of antigen-presenting cell (APC) immunosuppressive in a patient stratification strategy will sharply increase the number of patients who will benefit from ICIs.

INVESTIGADOR PRINCIPAL

GRUPO DE INVESTIGACIÓN RELACIONADO

GEMAT

Grup d'Enginyeria de Materials

School of Engineering

Ingeniería de Materiales

Su actividad se centra en tres grandes áreas: el desarrollo de nuevos materiales funcionales, la ingeniería de superficies y los biomateriales.